Physician profile
Alejandro Gonzalez
NPI 1538108097
$1,711.44
in general payments reported to CMS, 2019-2025
9 companies · $306 in 2025
The $306 reported for 2025 was more than what 76% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.82 · 2021: $287 · 2022: $653 · 2023: $154 · 2024: $282 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,225.62 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $155.98 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Shield Therapeutics INC | $111.43 | 2023-2025 | Accrufer |
| Amgen INC. | $70.33 | 2024-2025 | Tepezza, Krystexxa |
| Exact Sciences Corporation | $40.01 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $30.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.82 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.93 | 2022 | |
| Dexcom, INC. | $20.15 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.